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Abstract
Sialorrhea, also known as hypersalivation or ptyalism, is excessive salivation associated 
with neurological disorders or localized anatomical abnormalities in the oral cavity. 
Pathologic sialorrhea may develop due to hypersalivation, together with various neu-
rologic disorders including cerebral palsy, Parkinson’s disease, and amyotrophic lateral 
sclerosis, or as an adverse effect of medications. Sialorrhea results in numerous problem-
atic physical and psychosocial complications and has a significant negative impact on 
quality of life for both the patient and caregiver. The management of sialorrhea is best 
accomplished with a multidisciplinary team approach. Treatment options range from 
conservative measures such as observation, positioning, behavioral therapies, and phar-
macological therapy to more aggressive methods such as botulinum toxin injections or 
surgery. The physiology, etiology, assessment, and treatment of sialorrhea are outlined 
in this review.
Keywords: sialorrhea, hypersalivation, drooling, ptyalism, etiology, assessment, 
management
1. Introduction
Sialorrhea, also known as hypersalivation or ptyalism, is excessive salivation associated with 
neurological disorders or localized anatomical abnormalities in the oral cavity. Sialorrhea can 
be classified as anterior and posterior; both can occur separately or simultaneously. Posterior 
sialorrhea is the flowing of saliva from the tongue to the pharynx. Anterior sialorrhea results 
in salivary incontinence or involuntary spillage of saliva over the lower lip, known as drool-
ing. The underlying etiology is the excessive production of saliva or inability to retain saliva 
within the mouth due to reduced neuromuscular control of the tongue, oral tissues, and 
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impairment in the swallowing mechanism, all of which are necessary to move saliva from the 
oral cavity to the oropharynx and beyond [1]. Drooling is common in normally developed 
babies but subsides between the ages 15 and 36 months with the establishment of salivary 
continence. Sialorrhea after 4 years of age is generally considered pathologic. Pathologic sial-
orrhea may develop due to hypersalivation, together with numerous neurologic disorders 
including cerebral palsy (CP), Parkinson’s disease (PD), and amyotrophic lateral sclerosis 
(ALS), or as an adverse effect of medications. In children, the most common cause of sialor-
rhea is CP, which persists in 10–38% of these patients. In adults, the most common cause of 
sialorrhea is PD with a rate of 70–80% [2].
Whatever the cause is, drooling is bothersome, resulting in physical and psychosocial com-
plications. Physical complications include maceration of the skin around the mouth with 
secondary infection, bad odor, dehydration, speech disturbance, and interference with feed-
ing. People with drooling are also at increased risk for aspiration of saliva, food, or fluids 
into lungs, particularly when the normal reflex mechanisms such as gagging or coughing are 
impaired. The psychosocial complications include isolation, barriers to education (such as an 
inability to share books or computer keyboards), increased dependency and level of care, dam-
age to electronic devices, decreased self-esteem, and difficult social interaction [3]. Sialorrhea 
may have a significant negative impact on quality of life for both the patient and caregiver [1].
2. Physiology of salivation
The major salivary glands include parotid, submandibular, and sublingual glands; the largest 
being the parotid gland. These glands secrete saliva, which has a major role in lubrication, 
digestion, immunity, and maintenance of homeostasis in the human body [2]. The salivary 
secretion of parotid, submandibular, and sublingual glands is controlled mainly by para-
sympathetic nervous system, although sympathetic innervation has a minor influence. The 
parasympathetic fibers originate in the pons and medulla, and they synapse in the otic and 
submandibular ganglia. Postganglionic fibers originating from the otic ganglion regulate 
secretory functions of the parotid gland, while the postganglionic fibers from the subman-
dibular ganglion regulate secretory function of the submandibular and sublingual glands. 
Sympathetic innervation of these glands results in contraction of muscle fibers around the 
salivary ducts, which enhances the flow of saliva [3].
Salivary secretion is regulated through a reflex arch that produces several actions. The affer-
ent branch contains chemoreceptors in taste buds and mechanoreceptors in the periodontal 
ligament. Afferent innervations of cranial nerves V, VII, IX, and X carry impulses to salivary 
nuclei in the medulla oblongata. Efferent impulses are mainly parasympathetic as described 
above; they come from the chorda tympani nerve (a branch of the cranial nerve VII) and travel 
to the submandibular, sublingual, and other minor glands via lingual nerve (a branch of the 
cranial nerve V
3
). Efferent fibers to the parotid gland are supplied by lesser petrosal nerve 
(a branch of cranial nerve IX), which travel through the fibers of auriculotemporal nerve (a 
branch of the cranial nerve V
3
) and reach the gland [2].
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The major salivary glands provide 90% of the nearly 1.5 L of saliva that is produced every 
day. If salivary secretion is not stimulated, that is in basal state, 70% of total salivary secretion 
comes from the submandibular and sublingual glands. When stimulated, salivary secretion 
increases by five times, with the parotid glands delivering the greater amount of the saliva 
[3]. An example of an exogenous source causing stimulation is chewing [2]. There are two 
main types of saliva produced by the three major salivary glands; serous saliva is produced 
mainly by parotid glands by stimulation, which is thin and watery, while viscous saliva is 
produced by sublingual and submandibular glands throughout the day, which is thicker [4]. 
Both forms of these secretions can be problematic. Serous saliva results in watery saliva, con-
sistently spilling from the side of the mouth, and viscous saliva may be mucoid and sticky, 
which makes it harder to clear and causes a sensation of choking, associated with panic. It 
is important to distinguish between thin, runny saliva and thick, mucous secretions because 
the treatment options differ. The stimulation of cholinergic receptors produces thin, serous 
secretions, whereas that of beta-adrenergic receptors produces thick protein and mucus-rich 
secretions. Therefore, in the case of watery saliva secretions, anticholinergics can be preferred, 
whereas for thick mucus secretions, the addition of beta blockers may be beneficial [5].
3. Etiology of sialorrhea
Sialorrhea associated with neurologic illnesses is generally caused by impaired swallowing 
due to impaired neuromuscular function. Efficient coordination of various structures, namely 
the oral cavity, pharynx, larynx, and esophagus, is required for the neuromuscular activity of 
swallowing. The coordination of these structures forms three phases; the oral phase is under 
voluntary control, followed by the pharyngeal and esophageal phases, which are involuntary. 
Spontaneous swallowing is essential for the control of drooling. In children with neurologic 
disorders, drooling is similarly the result of inefficient tongue and/or bulbar control, thus 
impaired swallowing, rather than hypersalivation [2].
In children, mental retardation and CP are the most common causes of sialorrhea. Roughly, 
one in three children with CP is reported to have some degree of sialorrhea. Sialorrhea in CP 
is caused by oral motor dysfunction, dysphagia, and intraoral sensitivity disorder. Though 
underestimated, sialorrhea has significant clinical and social consequences concerning the 
overall health of these children, including dysphagia, respiratory health, and socioemotional 
aspects of both the children and their caregivers [4]. In adults, PD is the most common etiol-
ogy. Swallowing impairment, mostly in the oropharyngeal phase, is the major contributor to 
the pathophysiology of sialorrhea in PD patients, while an increase in the speed of salivary 
excretion might be a minor contributor. No increase in salivary production was demonstrated 
in scintigraphic studies in PD patients with sialorrhea, while the speed of salivary excretion of 
parotid glands in PD patients was significantly higher than normal controls with Tc-99 m scin-
tigraphy [6]. Similarly, in ALS, sialorrhea is not caused by increased production of saliva, but 
by the inability to swallow secretions because of tongue spasticity, weakness of face, mouth and 
pharyngeal muscles, and loss of oropharyngeal coordination and function [5]. Less common 
neurologic causes of sialorrhea are pseudobulbar palsy, bulbar palsy, and stroke (Table 1).
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Increased secretion of saliva frequently develops due to inflammation, such as teething, den-
tal caries, and oral cavity infections. Pregnancy is another significant cause of hypersecretion, 
usually related to hyperemesis gravidarum. It has an abrupt onset in the 2nd and 3rd week 
of conception with the rise of hormones and usually resolves during 2nd trimester [7]. Other 
causes of hypersecretion include side effects from medications (i.e., antipsychotics, tranquiliz-
ers, anticonvulsants, cholinergic agonists, and lithium), gastroesophageal reflux, toxin expo-
sure (i.e., mercury vapor, poisonous spider bites, mushrooms, insecticides), and rabies [3, 8]. 
Clozapine, an antipsychotic used in schizophrenia, is a rather common cause of sialorrhea, 
which manifests in 30–80% of patients taking the drug. Hypersalivation usually develops 
early in the treatment course and is typically more prominent at night [9].
Anatomic abnormalities are usually not the only cause of sialorrhea; however, most of the 
time, they exacerbate other causative conditions. Macroglossia (enlarged tongue) and oral 
incompetence may cause salivary spilling. A constantly open mouth due to nasal blockage or 
malocclusion and other orthodontic problems may compound oral incompetence; treatment 
of nasal problems and orthodontic correction can alleviate sialorrhea. Surgical defects occur-
ring after major head and neck surgeries may result in sialorrhea as well [3].
4. Assessment of sialorrhea
Assessment of the severity of sialorrhea and its impact on the quality of life for the patient and 
the caregivers assist in establishing a prognosis and appropriate management of the prob-
lem. History should be taken from the patient and the caregiver to understand the etiology 
and severity of the situation and its impact on the daily life. Use of medications, language 
and communication skills, cognition, respiratory health, and presence of gastroesophageal 
reflux disease should be questioned. In physical examination, oral cavity should be exam-
ined for sores on the lip and chin, dental problems, tongue size and movement, and tonsillar 
Systemic causes
• Neuromuscular/sensory dysfunction—cerebral palsy, Parkinson’s disease, mental retardation, motor neuron 
disease (ALS), pseudobulbar/bulbar palsy, stroke
• Medication side effects—antipsychotics (clozapine), tranquilizers, anticonvulsants, anticholinesterases, lithium
• Toxin exposure—mercury vapor, pesticides, snake poisoning, mushrooms
• Infection—rabies
• Gastric—gastroesophageal reflux
Local causes
• Oral Inflammation—teething
• Infection—dental caries, oral cavity infection, tonsillitis, peritonsillar abscess
• Anatomic—macroglossia, nasal blockage, oral incompetence, dental malocclusion, orthodontic problems, head 
and neck surgical defects
Physiological causes
• Pregnancy
Table 1. Etiology of sialorrhea.
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hypertrophy; nasal blockage, malocclusion, and jaw stability should be assessed. A neurologi-
cal examination should be carried out investigating the level of alertness, swallowing ability, 
motor skills, and sensory dysfunction of the patient. The nutrition and hydration status, head 
posture, and emotional state of the patient should also be evaluated [4, 10].
Objective and subjective measures have been developed to quantify sialorrhea. The objective test 
methods include radioisotope scanning, collection cups strapped to the patient’s chin for the mea-
surement of salivary flow, and direct observation of saliva loss such as counting the number of 
napkins used daily to contain excessive saliva production, measuring the weight of the towels or 
dental cotton rolls [4, 10]. The importance of objective methods is that they seem to be more sensi-
tive in detecting a reduction in sialorrhea or drooling than purely subjective assessments [11].
A variety of subjective scales for sialorrhea have been described. Subjective scales such as the 
drooling frequency and severity scale, the drooling rating scale, the drooling impact Scale, 
and visual analog scales can be given to patients or their caregivers to determine the qualita-
tive and quantitative consequences of the severity and impact of sialorrhea [4]. The drool-
ing frequency and severity scale is an easy comprehensive scale, which rates the severity of 
drooling on a five-point scale and the frequency of drooling on a four-point scale (Table 2) 
[12]. Subjective scales are useful and appropriate methods to measure changes in sialorrhea, 
because the impact on families, caregivers, and the patients themselves is of utmost impor-
tance when assessing satisfaction with the effectiveness of any treatment [4].
5. Management of sialorrhea
The management of sialorrhea continues to be a challenge in spite of various effective treat-
ment strategies to diminish saliva production. The flow of saliva from the oral cavity to the 
esophagus depends on numerous factors, such as cognitive and mental abilities, intact swal-
lowing, oral sensibility, lip closure, and ability to keep the head upright [1].
Drooling severity Points
Dry (never drools) 1
Mild (wet lips only) 2
Moderate (wet lips and chin) 3
Severe (clothing becomes damp) 4
Profuse (clothing, hands, tray, objects become wet) 5
Drooling frequency
Never drools 1
Occasionally drools 2
Frequently drools 3
Constantly drools 4
Table 2. Drooling frequency and severity scale.
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Treatment of sialorrhea is best accomplished with a multidisciplinary team approach. The 
complete history and physical examination of the patient, the assessment of the impact of 
drooling on quality of life, and the potential for improvement can be undertaken by the pri-
mary care physicians. Speech pathologists and occupational therapists provide education for 
swallowing mechanics to the patients and support their posture with devices such as the head 
back wheelchair. Dentists and orthodontists identify and correct dental and oral diseases and 
malocclusion. Otolaryngologists diagnose and treat causes of aerodigestive obstruction like 
macroglossia and adenotonsillar hypertrophy that contribute to drooling. Neurologists assess 
the severity and prognosis of neurologic conditions that result in drooling [3].
The goal of the treatment of drooling is a reduction in excessive salivary flow, while maintain-
ing a moist and healthy oral cavity. Avoidance of xerostomia (dry mouth) is essential. The two 
main approaches are:
1. Noninvasive modalities including positioning, improving eating and drinking skills, oral 
facial facilitation, speech therapy, biofeedback, positive and negative reinforcement, oral 
prosthetic devices, pharmacological therapy, and botulinum toxin
2. Invasive modalities including surgery and radiotherapy
Generally, no single approach is adequately effective, and usually, a combination of therapies 
is used. Primarily, reversible causes of drooling should be treated. Less invasive and revers-
ible methods are preferred before surgery is undertaken [10]. Behavioral approaches and 
therapies employed by speech pathologists are rarely curative, while systemic medications 
and surgical approaches may have severe and long-term adverse effects [1].
For minimal problems, in children younger than 4 years of age or in adults with unstable neu-
rologic function, observation may be the convenient choice. Minimal issues can be handled 
with a feeding program aimed at improving oral-motor control as well; nevertheless, this can 
rarely be helpful. Anatomical problems should be identified and treated, and adenotonsil-
lectomy should be undertaken, if necessary. Dental malocclusion and caries should be cor-
rected. Patients should be fitted with appropriate wheelchairs and braces, when required. A 
number of orthodontic appliances may be used, such as customized plates that fit the palate 
for improving lip closure or movable beads placed on the upper plate that stimulate tongue 
movement, thus helping to deflect saliva toward the pharynx [3].
Other conservative therapeutic options include positioning techniques, oral-motor, and 
speech therapies given by speech therapists, which improve oral awareness and motor con-
trol. Biofeedback and automatic cueing techniques may be utilized in patients with mild neu-
rologic dysfunction and drooling. These devices are used to associate a behavior with a cue, 
such as swallowing or wiping the face with a beep sound. Reinforcement methods, which are 
suggested behaviors such as encouraging patients for swallowing and wiping their faces and 
discouraging open mouth, can be used as an adjunct in moderate sialorrhea [3, 10].
Whenever sialorrhea continues to affect the patient’s health and quality of life in spite of 
these conservative measures, pharmacological therapy and other invasive therapies should 
be considered.
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5.1. Pharmacological therapy
Oral therapy for sialorrhea encompasses the use of anticholinergic agents such as glycopyr-
rolate, benztropine, scopolamine, and tropicamide. Anticholinergic agents work by downregu-
lating acetylcholine and ultimately decreasing saliva secretion through the parasympathetic 
autonomic nervous system. Glycopyrrolate oral solution is an anticholinergic agent that was 
the first drug approved in the United States for drooling in children with neurologic conditions 
and is generally well tolerated. However, anticholinergic agents are poorly tolerated by elderly 
patients. Glycopyrrolate actually has lower risk of central side effects, owing to its quaternary 
ammonium structure, that makes it impossible to pass the blood–brain barrier in large amounts. 
It is effective and safe at 1 mg, 3 times a day [2]. Studies have shown 70–90% response rates, but 
approximately 30–35% of patients discontinue the drug due to side effects such as excessive dry 
mouth, urinary retention, decreased sweating, skin flushing, irritability, and behavior changes 
[10]. Other undesirable adverse effects observed with such treatment include constipation, uri-
nary retention, tiredness, and drowsiness [11]. Anticholinergics are contraindicated in patients 
with glaucoma, obstructive uropathy, gastrointestinal motility disorders, and myasthenia gravis.
Intraoral tropicamide films provide short-term relief of sialorrhea. One study provided 
evidence that 1 mg of tropicamide resulted in significant visual analog scale score decrease 
and reduction in saliva volume in nondemented PD patients [2]. Transdermal scopolamine, 
applied as a patch behind the ear, was well tolerated in short-term studies, but its use was 
limited by side effects of urinary retention and blurred vision [3].
A comprehensive systematic review of the use of anticholinergics in children concluded that 
benztropine, given 3–3.8 mg per day, could be effective. A significant decrease in the mean 
score for drooling was reported with benzhexol hydrochloride (2 × 2 up to 2 × 3 mg daily). 
There was also some evidence for a marked decrease in drooling with glycopyrrolate [13]. 
Benztropine was also reported to show a significant reduction in the total salivation scores 
compared to botulinum toxins A and B in a study of mixed treatment network meta-analysis 
of randomized controlled trials on pharmacological interventions for treating sialorrhea asso-
ciated with neurological disorders [14].
Antireflux medication has also been suggested for use in drooling; however, there are no 
double-blind studies in the literature to offer evidence for this recommendation [2].
5.2. Botulinum toxin
The injection of botulinum toxin (BT) to the major salivary glands has grown in popularity 
because of its limited invasiveness and demonstrated effectiveness in many patients. It has 
been shown to improve quality of life of patients effectively with a low profile of side effects. 
However, it is important to take into account that the duration of the therapeutic effect is 
limited in time, generally lasting a few months [11].
The effect of BT in sialorrhea was first reported in PD patients [15]. This toxin is a potent 
neurotoxin that blocks the release of acetylcholine and a number of other neurotransmitters 
from synaptic vesicles; hence, it shows its effect by blocking cholinergic postganglionic para-
sympathetic fibers in sialorrhea [2].
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Currently, three type A and one type B toxin are approved for use in the US. These are 
OnabotulinumtoxinA (BOTOX®), AbobotulinumtoxinA (Dysport®), IncobotulinumtoxinA 
(Xeomin®), and RimabotulinumtoxinB (Neurobloc®/myobloc®) [2]. Both A and B types of 
BT are reported to be effective in treatment of sialorrhea, and both have a low profile of side 
effects [1].
BT can be injected in parotid and/or submandibular glands. The dose, concentration, and 
volume of injectate, number of injections, injection site, rate of injection, gauge of needle, and 
distance of needle tip from the neuromuscular junction are among the factors that can affect 
the diffusion and spread of BT, thus its efficacy in sialorrhea. A broad dose range of BT has 
been reported in various studies, specifically from 10 to 100 U of Botox®, from 20 to 300 U 
of Dysport® per patient, while usually 2500 U of Neurobloc® per patient is reported to be 
injected. The effect of BT on salivation lasts for 1.5–6 months [11]. Older age is significantly 
associated with longer benefit duration [16]. Sometimes the reduction in salivary secretion 
and improvement in drooling may not be correlated, owing to the variability of the factors 
that influence the severity of drooling and reduction of saliva secretion [2]. Patients with 
PD showed a more favorable safety-efficacy ratio than did patients with ALS, due to lower 
adverse events and longer benefit duration [16].
In a recent meta-analysis, eight randomized placebo-controlled trials involving 181 patients 
were reviewed. The study reported that BT improved drooling severity in patients with sial-
orrhea significantly in both adult and pediatric populations. Increased saliva thickness (3.9%), 
dysphagia (3.3%), xerostomia (3.3%), and pneumonia (2.2%) were reported as common side 
effects [1]. Adverse effects such as chewing difficulties and recurrent mandibular luxation 
have been reported [11]. BT therapy is reported to have many advantages over other noninva-
sive and invasive treatments. It is effective and minimally invasive with few side effects and 
a low risk of aspiration. However, it is expensive and temporary, and the need for repeated 
sedation can be troublesome with children [2].
Ultrasound guidance for intraglandular injection is preferred by some of the authors. Blind 
puncture of the superficial lobe of the parotid gland following anatomical landmarks is easier, 
because the structure is relatively superficial. Since the submandibular glands are normally 
nonpalpable, infiltration may be more challenging. Ultrasound easily identifies the glandular 
structures for infiltration, while avoiding accidental damage to other anatomical structures, 
the facial nerve in the case of injection into the parotid gland, or the facial vessels in the case 
of the submandibular gland [11].
Jongerius et al. compared the efficacy of BT injections to transdermal scopolamine. They 
reported that even though both treatments were successful in significantly lowering drooling 
parameters, patients treated with BT did not experience any side effects, while 40% of patients 
taking scopolamine reported severe adverse effects. The wide range of side effects and poten-
tial drug–drug interactions encountered with scopolamine and glycopyrrolate suggests that 
BT may be a safer option compared to systemic anticholinergics [13].
BT can also be used for empirical selection of patients who would, in the future, be good can-
didates for surgical treatment of the major salivary glands. In this way, patients who respond 
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well to BT injections can be treated more efficiently with surgery rather than receiving mul-
tiple injections. On the other hand, patients who do not respond well to BT may be considered 
as poor candidates for surgical treatment, because failure rates could be much higher owing 
to the contribution from minor salivary glands to the etiology of sialorrhea [17].
5.3. Radiation therapy
Radiation therapy to the salivary glands is a useful treatment option in elderly patients who 
are not candidates for surgery and cannot tolerate medications. Radiation causes xerostomia 
that lasts months to years. The dose may be changed to produce the desired effect, and it can 
be repeated if required. The main problem is that radiation can induce malignancies, but 
this does not happen until 10–15 years after treatment and therefore are less of a concern in 
patients who are elderly and debilitated [3].
5.4. Surgical treatment
While many patients are successfully treated with conservative methods and medical thera-
pies, a number of patients are not able to tolerate the side effects of medications. BT treatment 
is reported to show improvement in drooling, but surgery provides a larger and longer last-
ing effect. Surgeons should consider more aggressive interventions for patients with chronic 
sialorrhea secondary to neuromuscular dysfunction with the impairment of swallowing. 
In these cases, sublingual or submandibular gland excision, submandibular duct ligation, 
parotid duct ligation, submandibular or parotid duct rerouting, or any combination of the 
above procedures result in higher rates of success, both short term and long term, and they 
may be cost-effective compared to BT injections requiring multiple visits [18]. Nevertheless, 
it is important to mention that surgery has a risk of permanent consequences (especially 
xerostomia), and that it should be preferred only in severe cases who are not responsive to 
nonsurgical therapies and in whom sialorrhea has great impact on the health and quality of 
life of the individual and caregivers [5].
Tympanic neurectomy is now regarded as a historical technique used to denervate salivary 
glands. This technique is performed through the middle ear, where the tympanic plexus and 
chorda tympani travel before entering the major salivary glands. The procedure is relatively 
simple and fast, but salivary function returns within 6–18 months, when nerve fibers regener-
ate [3, 17].
Recently, a novel procedure, transoral endoscopic submandibular ganglion neurectomy, was 
performed in two cases of BT-resistant drooling. Six months follow-up was successful; how-
ever, long-term results are awaiting to be warranted [19].
The most definitive treatment of sialorrhea is to excise the major salivary glands or to ligate or 
reroute the major salivary ducts. Surgical management can be described by a combination parotid 
duct ligation or rerouting with either submandibular gland excision or submandibular duct 
rerouting. Preservation of salivation with decrease in drooling could be accomplished by rerout-
ing of the parotid and submandibular ducts to the posterior oropharynx with the advantage of 
no external scar. There may be a potential for aspiration after these procedures. Sublingual gland 
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excision is suggested as well when the submandibular ducts are rerouted to prevent formation 
of salivary retention cysts. Parotid duct ligation is a simple fast procedure without an external 
scar, which decreases the stimulated salivary flow. There may be a risk of sialocele development. 
The most definitive surgical procedure, which includes bilateral parotid duct ligation and sub-
mandibular gland excision, is highly successful, with nearly total elimination of sialorrhea, a low 
incidence of facial weakness, and significant patient and caregiver satisfaction [3].
The meta-analysis of surgical management using a variety of surgical procedures demonstrates 
significant subjective relief in 81.6% of pediatric patients with sialorrhea following surgery. 
Bilateral submandibular gland excision and parotid duct rerouting had the highest reported 
success rate of 87.8%. However, simple bilateral submandibular duct rerouting and bilateral 
submandibular duct rerouting with bilateral parotid duct ligation had similar levels of subjec-
tive success. Four-duct ligation had the lowest success rate at 64.1%. Although this procedure 
seems simpler and less invasive compared to other surgeries, it can cause significant pain and 
swelling, since the ligated glands continue to produce saliva for a period before atrophy occurs. 
Bilateral submandibular duct rerouting is a procedure that is more complex than a simple 
submandibular duct ligation. The reported success rates with this procedure are consistently 
good and similar to procedures involving submandibular gland excision. Limited data suggest 
that fibrosis of the gland occurs due to obstruction of the rerouted duct, ending up as an actual 
ligation of the duct, but in most of the patients, function is maintained in at least one gland [17].
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